Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 801–900 of 1,004
Konerman, M. C., Kulkarni, K. R., Toth, P. P., & Jones, S. R. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.01.004 · Cited by 16
Lv, X., Zhang, Y., Rao, S., Liu, F., Zuo, X., Su, D., Wang, M., Xia, M., Guo, H., Feng, D., et al. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-128 · Cited by 16
“Commons Attribution License (http://creativec reproduction in any medium, provided the or Lp(a), a low-density lipoprotein (LDL)-like particle synthesized in the liver [2], has been well known as an independent risk factor for CAD [3-6].”
BackgroundGenetics of Atherothrombosis and Thrombophilia
Mälarstig, A., & Hamsten, A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0101-z · Cited by 18
Self-citationLai, H., Chen, Q., Li, X., Ma, Y.-T., Xu, R., Zhai, H., Liu, F., Chen, B., & Yang, Y. (2015) · PubMed · Cited by 19
Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
Shahreyar, M., Salem, S. A., Nayyar, M., George, L. K., Garg, N., & Koshy, S. K. G. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.04.170447 · Cited by 18
“independent risk factor for cardiovascular disease in epidemiologic studies.(15)”
BackgroundUntying the correlation between apolipoproteins and rheumatoid arthritis
Makkar, R., Behl, T., Kumar, A., Uddin, M. S., & BUNGAU, S. G. (2020) · Inflammation Research · doi:10.1007/s00011-020-01410-5 · Cited by 16
Zabalza, M., Subirana, I., Lluís-Ganella, C., Sayols-Baixeras, S., de Groot, E., Arnold, R. J., Cenarro, A., Ramos, R., Marrugat, J., & Elosúa, R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.10.023 · Cited by 18
Lipoprotein(a): the underestimated cardiovascular risk factor
Thompson, G. R., & Seed, M. (2013) · Heart · doi:10.1136/heartjnl-2013-304902 · Cited by 17
Modeling gene interactions in polygenic prediction via geometric deep learning
Li, H., Zeng, J., Snyder, M. P., & Zhang, S. (2024) · Genome Research · doi:10.1101/gr.279694.124 · Cited by 16
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Parhofer, K. G., Julius, U., Herzog, A. L., Krüger, T., Weinmann‐Menke, J., Heine, G. H., Cao, H., Schorr, J., Ferber, P. C., Wang, J., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag073 · Cited by 15
“3 Epidemiological, genetic, and Mendelian randomization studies have established elevated Lp(a) as an inherited, independent, and causal risk factor for cardiovascular disease (CVD), 4–7 with lifestyle measures such as diet and exercise having minimal influence on serum levels.”
Zhou, L., Peng, F., Li, J., & Gong, H. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12024 · Cited by 15
“Clarke et al (16) found that two lipoprotein variants were associated with an increased risk of coronary disease using a novel gene chip containing single‐nucleotide polymorphisms.”
BackgroundLi, Q., Yin, K., Ma, H., Liu, H.-H., Li, S., Luo, X., Hu, R., Zhang, W., Lv, Z.-S., Niu, X.-L., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.008 · Cited by 15
Lu, J., Wang, Z., Zhang, J., Jiao, F., Zou, C., Han, L., & Jiang, G. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100528 · Cited by 15
“Genetic variants related to Lp(a) were obtained from a GWAS in the Precocious Coronary Artery Disease cohort of European descent (18).”
MethodAkyol, Ö., Yang, C.-Y., Woodside, D. G., Chiang, H., Chen, C., & Gotto, A. M. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01209-3 · Cited by 15
“Data from genome-wide association and PRO-CARDIS (Precocious Coronary Artery Disease) cohorts linked 2 LPA single nucleotide polymorphisms to increased Lp(a) levels and coronary artery disease risk [88].”
MethodLP(a): The new marker of high cardiovascular risk
Averna, M. R., & Cefalu, A. B. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103845 · Cited by 17
Lipoprotein(a) and prothrombotic effects: Evidence from a genetic association study
Olmastroni, E., Katzmann, J. L., Galimberti, F., Laufs, U., & Catapano, A. L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.01.021 · Cited by 15
Lipoprotein(a)—clinical aspects and future challenges
Kurt, B., Soufi, M., Sattler, A., & Schaefer, J. R. (2015) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-015-0075-z · Cited by 19
“They found in their found a significant reduction of CAD events under LDL apheresis compared to the time before this treatment [23].”
InfluentialScreening for and Management of Elevated Lp(a)
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0417-8 · Cited by 17
Cenarro, A., Puzo, J., Ferrando, J., Mateo‐Gállego, R., Bea, A. M., Calmarza, P., Jarauta, E., & Civeira, F. (2013) · Metabolism · doi:10.1016/j.metabol.2013.10.014 · Cited by 16
“The kringle IV-2 sequence is present in a variable number of identically repeated copies (from 3 to > 60) and the number of kringle IV-2 repeats is inversely correlated with the Lp(a) concentration [4,12], but positively associated with the development of myocardial infarction, even after adjustment”
BackgroundBoffa, M. B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0622-1 · Cited by 15
“Many assays report a mass concentration of the protein component 69 Page 2 of 11 Curr Atheroscler Rep (2016) 18: 69”
BackgroundMethodInfluentialDong, H., Cong, H., Wang, J., Jiang, Y., Liu, C., Zhang, Y., Zhu, Y., & Wang, Q. (2020) · Journal of International Medical Research · doi:10.1177/0300060520965353 · Cited by 16
Radiation-induced cardiovascular disease: an overlooked role for DNA methylation?
Sallam, M., Benotmane, M. A., Baatout, S., Guns, P., & Aerts, A. (2021) · Epigenetics · doi:10.1080/15592294.2021.1873628 · Cited by 15
“[249] Clarke R, Peden JF, Hopewell JC, et al.”
Parthymos, I., Kostapanos, M. S., Mikhailidis, D. P., & Florentin, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab052 · Cited by 15
Cui, K., Wang, H., Yin, D., Zhu, C., Song, W., Wang, H., Jia, L., Zhang, D., Song, C., Feng, L., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.807925 · Cited by 15
Lipoprotein(a): cardiovascular risk and emerging therapies
Fujino, M., & Nicholls, S. J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2197593 · Cited by 15
“Since Lp(a) is primarily genetically determined by KIV repeats, which determine the size of the Apo(a) isoform and are determined by numerous single nucleotide polymorphisms (SNPs) and SNP-scores, this assumption is met and is probably one of the best phenotypes to study by MR methods [11,36,37].”
BackgroundAssociation of statin use and increase in lipoprotein(a): a real-world database research
Feng, T., Li, Y., Xue, X., Yang, W. Y. L., Li, Q., Huang, Y., Zhu, T., Wang, J., Xu, L., Li, X., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01155-x · Cited by 15
Magni, P. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.03.004 · Cited by 17
Lipoprotein(a)—antisense therapy
Vogt, A. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00096-2 · Cited by 16
Toro, R., Segura, E., Núñez-Cortés, J. M., Pedro‐Botet, J., Quezada-Feijoó, M., & Mangas, A. (2015) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2015.02.001 · Cited by 15
Zheng, W., Chilazi, M. J., Park, J., Sathiyakumar, V., Donato, L. J., Meeusen, J. W., Lazo, M., Guallar, E., Kulkarni, K. R., Jaffe, A. S., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023136 · Cited by 15
Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin
Tuteja, S., Qu, L., Vujković, M., Dunbar, R. L., Chen, J., DerOhannessian, S. L., & Rader, D. J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008461 · Cited by 15
“4,13 It is unknown whether genetic variation at these loci also mediates the effects of lipid-lowering medications.”
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Patel, R. S., Morris, A. A., Ahmed, Y., Kavtaradze, N., Sher, S., Su, S., Zafari, A. M., Din-Dzietham, R., Waddy, S. P., Vaccarino, V., et al. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.41 · Cited by 14
Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men
Ezzat, D., Lopez, D. M., Claggett, B. L., Li, L., Mohammadnia, N., Schuermans, A., Hemeryck, J., Chang, A., Murillo, S., O’Donoghue, M. L., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag252 · Cited by 14
Zierfuss, B., Höbaus, C., Feldscher, A., Hannes, A., Mrak, D., Koppensteiner, R., Stangl, H., & Schernthaner, G.-H. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.10.002 · Cited by 16
The Role of Lipoprotein(a) in Peripheral Artery Disease
Pavlatos, N., & Kalra, D. K. (2024) · Biomedicines · doi:10.3390/biomedicines12061229 · Cited by 17
Fathieh, S., Tang, O., Gray, M. P., Zanchin, C., Vernon, S. T., Genetzakis, E., Tran, C., SULLIVAN, D. R., Nicholls, S. J., Celermajer, D. S., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf323 · Cited by 14
Lipoprotein (a): A new target for pharmacological research and an option for treatment
Pirillo, A., & Catapano, A. L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.021 · Cited by 16
No large-effect low-frequency coding variation found for myocardial infarction
Holmen, O. L., Zhang, H., Zhou, W., Schmidt, E. M., Hovelson, D. H., Langhammer, A., Løchen, M., Ganesh, S. K., Mathiesen, E. B., VATTEN, L. J., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu175 · Cited by 16
“Ile4399Met, is part of the SLC22A3-LPAL2-LPA gene cluster located at 6q26-27 that has previously been associated with CAD (1,23,24) and apolipoprotein(a) levels (25).”
BackgroundA Genetic Risk Score is Associated with Statin-Induced Low-Density Lipoprotein Cholesterol Lowering
Leusink, M., der Zee, A. H. M., Ding, B., Drenos, F., van Iperen, E. P. A., Warren, H. R., Caulfield, M. J., Cupples, L. A., Cushman, M., Hingorani, A. D., et al. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.8 · Cited by 14
Tuteja, S., Wang, L., Dunbar, R. L., Chen, J., DerOhannessian, S. L., Marcovina, S. M., Elam, M. B., Lader, E. W., & Rader, D. J. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000289 · Cited by 15
Page, M. M., & Watts, G. F. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000842 · Cited by 14
“2) [37], and therefore with higher plasma concentrations of Lp(a) [25].”
BackgroundPharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Cui, K., Yin, D., Zhu, C., Yuan, S., Wu, S., Feng, L., & Dou, K. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.03.024 · Cited by 14
Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study
Šuran, D., Vošner, H. B., Završnik, J., Kokol, P., Sinkovič, A., Kanič, V., Kokol, M., Naji, F. H., & Završnik, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.923797 · Cited by 16
Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions
Hageh, C. A., Chacar, S., Ghassibe‐Sabbagh, M., Platt, D. E., Henschel, A., Hamdan, H., Gauguier, D., Murr, Y. E., Alefishat, E. A., Chammas, E., et al. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s394134 · Cited by 16
Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population
Hussain, Z. B., Iqbal, J., Liu, H., & Zhou, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123586 · Cited by 16
Dong, W., Zhong, X., Yuan, K., Miao, M.-Y., Zhai, Y., Che, B., Xu, T., Xu, X. M., & Zhong, C. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad070 · Cited by 14
Shapiro, D., Lee, K. D., Asmussen, J. K., Bourquard, T., & Lichtarge, O. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029103 · Cited by 14
Koch, W., Mueller, J. C., Schrempf, M. C., Wolferstetter, H., Kirchhofer, J., Schömig, A., & Kastrati, A. (2012) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2012.00739.x · Cited by 17
“These alleles were reported to be associated with elevated plasma Lp(a) and increased cardiovascular risk (Luke et al., 2007; Shiffman et al., 2008a, b; Chasman et al., 2009; Clarke et al., 2009).”
BackgroundInfluentialToth, P. P. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.045 · Cited by 14
Ferraz‐Amaro, I., WINCHESTER, R. J., Gregersen, P. K., Reynolds, R. J., Wasko, M. C., Oeser, A., Chung, C. P., Stein, C., Giles, J. T., & Bathon, J. M. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39862 · Cited by 15
“90th percentile 113 (21) 36 (18) 39 (20) 38 (23) Previous cardiovascular event 61 (11) 0 (0) 21 (11) 40 (24) Comorbidity and therapy Hypertension 235 (42) 76 (38) 71 (36) 88 (52) Systolic blood pressure, mean 6 SD mm Hg 129 6 20 128 6 19 125 6 19 133 6 20 Diastolic blood pressure, mean 6 SD mm Hg 76 6 10 76 6 9 76 6 1…”
Lipoprotein(a)-apheresis in the light of new drug developments
Vogt, A. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.025 · Cited by 14
“[10] Clarke, R, Peden, JF, Hopewell, JC, et al.”
Lipoprotein(a): the common, likely causal, yet elusive risk factor for cardiovascular disease
Kamstrup, P. R. (2017) · Journal of Lipid Research · doi:10.1194/jlr.c079111 · Cited by 14
Weiss, M. C., Berger, J. S., Gianos, E., Fisher, E. A. A., Schwartzbard, A. Z., Underberg, J. A., & WEINTRAUB, H. S. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.005 · Cited by 14
Enkhmaa, B., Anuurad, E., Zhang, W., Li, C., Kaplan, R. C., Lazar, J., Merenstein, D., Karim, R., Aouizerat, B. E., Cohen, M. H., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p084517 · Cited by 14
Pedoman Tatalaksana Dislipidemia PERKI 2013
Erwinanto, E., Santoso, A., Putranto, J. N., Tedjasukmana, P., Suryawan, R., Rifqi, S., & Kasiman, S. (2015) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v34i4.385 · Cited by 18
Lasek‐Bal, A., Kula, D., Urbanek, T., Puz, P., Szymszal, J., Jarząb, M., Halczok, M., Cyplinska, R., Bal, W., Labuz-Roszak, B. M., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01170 · Cited by 14
Anderson, J. L., Knight, S., May, H. T., Horne, B. D., Bair, T. L., Huntinghouse, J. A., Rollo, J. S., Muhlestein, J. B., & Carlquist, J. F. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.05.009 · Cited by 15
“A case for causality of Lp(a) cholesterol also has been made on the basis of the Mendelian randomization principle20: randomly assorted LPA genotypes at birth (unconfounded bybehavioral or environmental factors) predict Lp(a), and LPA and Lp(a) predict CAD.”
BackgroundInfluentialSong, P., Seok, J. M., Kim, W. S., Lee, Y. T., Kim, D., & Kim, G. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.039 · Cited by 15
A pan-genome approach to decipher variants in the highly complex tandem repeat of LPAPreprint
Chin, C.-S., Behera, S., Metcalf, G., Gibbs, R. A., Boerwinkle, E., & Sedlazeck, F. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.08.495395 · Cited by 15
Grüneis, R., Weißensteiner, H., Lamina, C., Schönherr, S., Forer, L., Maio, S. D., Streiter, G., Peters, A., Gieger, C., Kronenberg, F., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100306 · Cited by 15
“Additionally, we also stratified our data for rs10455872 and rs3798220 (known proxy SNPs for LMW isoforms (46) and high Lp(a)) to investigate the interplay between these two variants and KIV-2 4925G>A, but no overlap between these variants was evident (supplemental Figs.”
MethodOrfanos, P., Fonseca, A. F., Hu, X., Gautam, R., Montgomery, G., Studer, R. L., Kaur, J., Saxena, N., & Kaushik, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294250 · Cited by 13
Fichtner, I., Macchi, C., Rizzuto, A. S., Carugo, S., Corsini, A., & Ruscica, M. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.09.004 · Cited by 13
“These SNPs are strongly correlated with elevated lipoprotein(a) levels and a higher risk of coronary disease [16].”
BackgroundInflammatory and Lipid Biomarkers in Early Atherosclerosis: A Comprehensive Analysis
Муратович, Н. А., Витальевна, К. К., & Malyarevskaya, O. V. (2024) · Life · doi:10.3390/life14101310 · Cited by 13
“Clustering analysis revealed two distinct patient subgroups:”
Shishikura, D., Kataoka, Y., Nicholls, S. J., Ray, K. K., Puri, R., Kusumoto, H., Yamauchi, Y., Sakane, K., Fujisaka, T., Morita, H., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.019 · Cited by 13
Lan, Z., Ding, X., Yang, W., Yuan, J., Yu, Y., Yu, L., Dai, X. D., Wang, Y., & Zhang, J. (2025) · European Radiology · doi:10.1007/s00330-024-11313-2 · Cited by 13
“Mendelian randomization studies [32], genome-wide association studies [33], and clinical studies [34] have demonstrated that Lp (a) increases the risk of cardiovascular disease and elevates the incidence of adverse cardiovascular events.”
The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?
Boffa, M. B., & Koschinsky, M. L. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000499 · Cited by 15
Zhang, Y., Jin, J., Cao, Y., Liu, H., Zhang, H., Guo, Y., Wu, N., Gao, Y., Hua, Q., Li, Y., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02546-y · Cited by 13
Fatty acids and aortic valve stenosis
Plunde, O., & Bäck, M. (2021) · Kardiologia Polska · doi:10.33963/kp.a2021.0003 · Cited by 13
Khera, A. V., Wang, M., Chaffin, M. D., Emdin, C. A., Samani, N. J., Schunkert, H., Watkins, H. C., McPherson, R., Erdmann, J., Elosúa, R., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003598 · Cited by 14
Self-citationGenetics of aortic valve disease
Ackah, R. L., Yasuhara, J., & Garg, V. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001028 · Cited by 14
Farina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 14
“As a limitation, genetic information regarding SNPs in the LPA gene is predominantly limited to European populations, while it is known that Lp(a) concentrations in various ethnicities are less dependent on LPA SNPs alone [120,121].”
BackgroundAll we need to know about lipoprotein(a)
Bess, C., Mehta, A., & Joshi, P. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.05.007 · Cited by 17
Song, Z., Wu, H., Cao, H., & Qin, L. (2014) · BioMed Research International · doi:10.1155/2014/370670 · Cited by 14
“In the study by Clarke et al. rs3798220 and rs10455872 are strongly associated with serum Lp(a) levels in Caucasians [9].”
BackgroundResultInfluentialMangalmurti, S. S., & Davidson, M. H. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0190-3 · Cited by 15
“However, certain genetic variants of Lp (a) show strong correlations to cardiovascular risk [21, 22], suggesting that risk stratification with certain subtypes of Lp (a) may be more effective that simply checking Lp (a) levels.”
Important Considerations for Treatment with Dietary Supplement versus Prescription Niacin Products
Backes, J. M., Padley, R. J., & Moriarty, P. M. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.03.2265 · Cited by 14
“5-fold) for coronary disease.(23) In addition to decreasing LDL-C and TGs, niacin therapy has been shown, in some cases, to reduce circulating Lp(a) levels by as much as 30% or more.”
BackgroundPCSK9 Inhibition: Current Concepts and Lessons from Human Genetics
Rodríguez, F., & Knowles, J. W. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0487-8 · Cited by 13
Carotid Intima-Media Thickness in Asymptomatic Subjects With Low Lipoprotein(a) Levels
Kotani (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr849w · Cited by 13
“conducted on the significant association among Lp(a) levels, Lp(a)-related gene polymorphisms and atherosclerosis [32, 33].”
Genetic Analysis in Cardiovascular Disease: A Clinical Perspective
Ho, E. C., Bhindi, R., Ashley, E. A., & Figtree, G. A. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e318207ffac · Cited by 15
Genetic analysis of emerging risk factors in coronary artery disease
van Iperen, E. P. A., Sivapalaratnam, S., Holmes, M. V., Hovingh, G. K., Zwinderman, A. H., & Asselbergs, F. W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.008 · Cited by 15
“This is in keeping with recent genetic studies including that by Clarke et al., which identi fi ed two common SNPs in the LPA gene that had an associationwith both the Lp(a) lipoprotein level and the risk of CAD [6].”
Svensson, T., Kitliński, M., Engström, G., & Melander, O. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176029 · Cited by 15
Liu, S.-L., Wu, N., Guo, Y., Zhu, C., Gao, Y., Sun, J., Xu, R., Liu, G., Dong, Q., & Li, J. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136591 · Cited by 13
Coassin, S., Hermann‐Kleiter, N., Haun, M., Wahl, S., Wilson, R., Paulweber, B., Kunze, S., Meitinger, T., Strauch, K., Peters, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232073 · Cited by 13
Coassin, S., Chemello, K., Khantalin, I., Forer, L., Döttelmayer, P., Schönherr, S., Grüneis, R., Chong-Hong-Fong, C., Nativel, B., Ramin‐Mangata, S., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003489 · Cited by 13
Nora, C., Zhang, L., Castro, R. J., Marx, A., Carman, H. B., Lum, T., Tsimikas, S., & Hong, M. Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.013 · Cited by 13
“Evidence from genetic and clinical studies has consistently demonstrated that elevated LDL-C (>130 mg/dL) and Lp(a) (>75 nM) are associated with a higher risk of CVD [9–12].”
Xie, H., Hai, B., Wu, M., Qiu, C., Liu, M., Dong, C., & Guo, Z. (2014) · Molecular Genetics and Genomics · doi:10.1007/s00438-014-0866-9 · Cited by 13
Libby, P. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.08.007 · Cited by 13
Myocardial ischemia and its complications
Fishbein, G. A., Fishbein, M. C., Wang, J., & Buja, L. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822224-9.00022-0 · Cited by 20
Thomas, P. E., Vedel‐Krogh, S., & Kamstrup, P. R. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001168 · Cited by 12
Nomura, S. J. O., Bhatia, H. S., Garg, P. K., Karger, A. B., Guan, W., Cao, J., Shapiro, M. D., & Tsai, M. Y. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100903 · Cited by 15
“Lp(a) [5,24 – 27], hs-CRP [6 – 9] and tHcy [10 – 14] have all been shown to be associated with ASCVD risk.”
Hoogeveen, R. C., Diffenderfer, M. R., Lim, E., Liu, C., Ikezaki, H., Guan, W., Tsai, M. Y., & Ballantyne, C. M. (2025) · Nutrients · doi:10.3390/nu17081324 · Cited by 12
Anchouche, K., Baass, A. W., & Thanassoulis, G. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110929 · Cited by 13
Cardiovascular Implications of Lipoprotein(a) and its Genetic Variants
El-Menyar, A. A., Khan, N. A., Almahmeed, W. A., Suwaidi, J. M. S. A., & Al-Thani, H. A. S. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.04.012 · Cited by 12
Lipoprotein (a) in primary cardiovascular disease prevention is actionable today
Parcha, V., & Bittner, V. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100581 · Cited by 16
“However, it is important to note that these findings are limited to specific LPA gene variants (e.g., rs3798220, rs10455872) [95] and have not been consistently reproduced in broader populations.”
Inflammation reprogramming and immunomodulation: Next-generation treatments for atherosclerosis
Choudhury, R. P., Hargreaves, R., Chai, J., & Fisher, E. A. A. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102288 · Cited by 15
“28 31 The results of phase 3 clinical trials evaluating the effects of Lp(a) reduction with siRNA are ongoing, 32 testing pela-carsen in the HORIZON trial 33 and olpasiran in the OCEAN(a) trial.”
Lipoprotein(a) and risk of dementia: findings from three cohort studies
Thomas, P. E., Vedel‐Krogh, S., Nielsen, S. F., Nordestgaard, B. G., Frikke‐Schmidt, R., & Kamstrup, P. R. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf465 · Cited by 12
The biology of lipoprotein(a): From genetics to molecular mechanisms
Atallah, Nasrallah, N., Harb, T., Gerstenblith, G., & Leucker, T. M. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70133 · Cited by 13
“7 Like LDL-C, Lp(a) can infiltrate the arterial intima, where its lipid content contributes to foam cell formation.”
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 14
“71 So far, targeted therapies for Lp(a) are limited and outcome trials assessing the benefits of Lp(a) reduction, such as the Lp(a)HORIZON study, 72 are currently underway.”
Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a)
Poller, W. C., Dreger, H., Morgera, S., Berger, A., Flessenkämper, I., & Enke-Melzer, K. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.032 · Cited by 12
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.